Alpha 2.0
Login Register
» Articles » PMID: 27873177

Eculizumab Treatment Improved Renal Hemosiderosis in a Patient with Paroxysmal Nocturnal Hemoglobinuria

Overview
Journal Int J Hematol
Specialty Hematology
Date 2016 Nov 23
PMID 27873177
Citations 1
Authors
Seiko Iki
Kazuyuki Ohgi
Kenshi Suzuki
Affiliations
Soon will be listed here.
Citing Articles

Even mild hemolysis in paroxysmal nocturnal hemoglobinuria could severely compromise the quality of life due to long-term sustained intolerant fatigue.

Sakai K Leuk Res Rep. 2020; 14:100224.

PMID: 33083224 PMC: 7554027. DOI: 10.1016/j.lrr.2020.100224.

References
1.
Rimola J, Martin J, Puig J, Darnell A, Massuet A . The kidney in paroxysmal nocturnal haemoglobinuria: MRI findings. Br J Radiol. 2004; 77(923):953-6. DOI: 10.1259/bjr/51760601. View
2.
Tracz M, Alam J, Nath K . Physiology and pathophysiology of heme: implications for kidney disease. J Am Soc Nephrol. 2007; 18(2):414-20. DOI: 10.1681/ASN.2006080894. View
3.
Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H . Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial. Int J Hematol. 2011; 93(1):36-46. DOI: 10.1007/s12185-010-0748-9. View